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Abstract
Background: Human Subjects protections approaches, specifically those relating to research review board oversight,
vary throughout the world. While all are designed to protect participants involved in research, the structure and specifics
of these institutional review boards (IRBs) can and do differ. This variation affects all types of research, particularly
implementation research.
Methods: In 2001, we began a series of inter-related studies on implementing evidence-based collaborative care for
depression in Veterans Health Administration primary care. We have submitted more than 100 IRB applications,
amendments, and renewals, and in doing so, we have interacted with 13 VA and University IRBs across the United States
(U.S.). We present four overarching IRB-related themes encountered throughout the implementation of our projects,
and within each theme, identify key challenges and suggest approaches that have proved useful. Where applicable, we
showcase process aids developed to assist in resolving a particular IRB challenge.
Results: There are issues unique to implementation research, as this type of research may not fit within the traditional
Human Subjects paradigm used to assess clinical trials. Risks in implementation research are generally related to breaches
of confidentiality, rather than health risks associated with traditional clinical trials. The implementation-specific challenges
discussed are: external validity considerations, Plan-Do-Study-Act cycles, risk-benefit issues, the multiple roles of
researchers and subjects, and system-level unit of analysis.
Discussion:  Specific aspects of implementation research interact with variations in knowledge, procedures, and
regulatory interpretations across IRBs to affect the implementation and study of best methods to increase evidence-
based practice. Through lack of unambiguous guidelines and local liability concerns, IRBs are often at risk of applying both
variable and inappropriate or unnecessary standards to implementation research that are not consistent with the spirit
of the Belmont Report (a summary of basic ethical principles identified by the National Commission for the Protection
of Human Subjects of Biomedical and Behavioral Research), and which impede the conduct of evidence-based quality
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improvement research. While there are promising developments in the IRB community, it is incumbent upon
implementation researchers to interact with IRBs in a manner that assists appropriate risk-benefit determinations and
helps prevent the process from having a negative impact on efforts to reduce the lag in implementing best practices.
Background
Human Subjects protections approaches, specifically
those relating to research review board oversight, vary
throughout the world. While all are designed to protect
participants involved in research, the structure and specif-
ics of these institutional review boards (IRBs) can and do
differ. Central review boards, dual systems of central and
local review, review boards affiliated with universities or
hospitals, or un-affiliated independent review boards are
used to review research protocols [1]. Within the U.S., the
IRB system is struggling to effectively manage an increase
in workload, specialization of scientific protocols,
increased regulatory burden, and increased responsibili-
ties beyond risk-benefit assessments to include conflict of
interest, environmental impact review, HIPAA (Health
Insurance Portability and Accountability Act), and others
[2]. Nowhere is the result of these issues more prevalent
than in IRB review of implementation research.
Implementation research in health care is characterized by
a focus on evaluating evidence-based quality improve-
ment [3] and often involves partnerships between
researchers and clinicians across multiple sites [4]. As a
result, implementation research faces many of the same
human subjects challenges as other types of multi-site
studies and research involving a quality improvement
(QI) component [4].
The defining issue of human subjects protection within
implementation research is the decision of whether or not
implementation research should undergo IRB review. This
is not always clear, particularly in studies with a QI ele-
ment. There are several key determinations regarding
implementation studies, beginning with a determination
of whether the activity is actually research and, therefore,
reviewable. Subsequent risk-benefit determinations
include: whether human subjects are involved, whether
the criteria for minimal risk definitions are met, what type
of consent mechanisms are appropriate, and how to
weigh individual risk of breach of confidentiality (often
the primary risk) with potential societal benefit. These
determinations derive from ethical, regulatory, and liabil-
ity-related principles and demands, as well as from each
particular IRB's interpretation of the risk- benefit issues
given local issues and concerns. Currently, there is no offi-
cial consensus on whether and how to review QI research,
or other research types with QI elements, such as imple-
mentation research [5-10]. Whether appropriate or not,
once a QI research protocol begins IRB review, it is thrust
into a process that may not be optimal for balancing risk-
benefit issues.
The number of complex, multi-site studies has increased
over the past three decades, imposing a greater burden on
IRBs and potentially slowing review of all types of studies.
Researchers in the United States (U.S.) and elsewhere
report great variability in the way IRBs evaluate multi-site
protocols, time required for approval, and documentation
of consent in studies [11-16]. Greene and Geiger's litera-
ture review of IRB approvals for multicenter trials and
observational studies within the U.S., outlines the varia-
bility in IRB review processes and its potential effects on
research [17].
McWilliams reported that 31 IRBs generated study-risk
determinations from minimal to high for the same genetic
epidemiology protocol, resulting in 7 expedited reviews
and 24 full reviews across the sites. They reported a mean
of 32 (range 9–72) days for those sites undergoing expe-
dited review of their multi-site study, and a mean of 82
days (range 13–252) for the same protocol experiencing
full review at other sites. In their study of IRB variation,
Stair et al. experienced a median of 38 days for review and
approval (range 26–62) [16]. This variability can result in
disparities in application, be detrimental to the conduct of
the study, increase the time needed to conduct the study,
and increase costs [7,11,12]. The use of Centralized IRBs
may remediate the issue of variability, but researchers
should remain cautiously optimistic, as the literature from
countries with a centralized review mechanism, such as
the United Kingdom (U.K.), suggest that not all chal-
lenges faced by multi-site studies are resolved. Tod et al.
report that while multi-site research in the U.K. is now
overseen by Multi-centre Research Ethics Committees,
this addition of central review has not eliminated the need
to also seek Local Research Ethics Committee approval.
Critics of the system feel that this has created "an ineffi-
cient two-tier system of ethical review" [18]. Long delays
have been reported from the time of initial submission
until approval. Cassell and Young raise similar concerns
in their discussion of U.K. Human Subjects review [19].
Research protocols within the U.S. Department of Veter-
ans Affairs (VA) are not immune from these challenges
[20]. The VA healthcare system shares some similarities
with the Canadian or British Health Care systems, in that
it provides care to all veterans, but differs in that it has a
tiered payment system. Some veterans qualify for totalImplementation Science 2008, 3:10 http://www.implementationscience.com/content/3/1/10
Page 3 of 12
(page number not for citation purposes)
care, or total care for specific service-related conditions or
disabilities, at no expense to the individual, while other
veterans receive care through the VA's integrated health-
care network on a fee-for-service basis.
The purpose of this paper is two-fold. First, we address
and provide approaches and process aids for common
human subjects protection challenges, focusing on those
relevant to implementation research, and using our
research within the VA as an example. The second purpose
is to support the development of future improvements in
both IRB and implementation processes that will enhance
research/clinical partnerships. This article is one in a Series
of articles documenting implementation science frame-
works and approaches developed by VA's Quality
Enhancement Research Initiative (QUERI). QUERI is
briefly outlined in Table 1 and is described in more detail
in previous publications [21,22]. The Series' introductory
article [23] highlights aspects of QUERI that are related
specifically to implementation science and describe addi-
tional types of articles contained in the QUERI Series.
Methods
In 2001, we began a series of inter-related studies on
implementing evidence-based collaborative care for
depression in VA primary care known by the acronyms
TIDES (Translating Initiatives for Depression into Effec-
tive Solutions), WAVES (Well-being Among Veterans
Enhancement Study), and COVES (Cost and Value of Evi-
dence-based Solutions for Depression) for the initial stud-
ies, and ReTIDES (Regional TIDES) for the subsequent
regional rollout (Table 2). Our VA-funded multi-site
projects required a two-step approach to obtain necessary
IRB approval. Because our projects represent collabora-
tion among four regional health services research centers
with Principal or Co-Principal Investigators at each of
these sites, protocols had to be approved by their respec-
tive IRBs on the basis of Investigator involvement. Then
each local Site Principal Investigator (PI) participating in
the implementation research submitted the protocol to
their IRB with our assistance. The sites we work with were
either covered by their own resident VA IRB or an affili-
ated University IRB. We have submitted a combined total
of more than 100 IRB applications, amendments, and
renewals in the past six years for these four projects, and
in doing so have interacted with six resident VA IRBs and
seven contractually affiliated University IRBs across the
United States.
In Table 3, we present the four overarching IRB-related
themes encountered throughout the implementation of
our projects, including items specific to implementation
research, operating within multiple health care systems/
sites, coordinating with multiple local site PIs, and man-
aging differences among multiple IRBs. Within each issue,
we identify key challenges and suggest approaches that
have proved useful and may aid other researchers. Where
applicable, we showcase process aids developed to assist
in resolving a particular IRB challenge. The process aids
are included as additional files and range from process
guidelines through examples of explanatory material to a
relational tracking database. Table 3 provides the structure
and order for the paper. Many of these themes and chal-
lenges are interrelated and may overlap and/or comple-
ment each other among sections. As always, IRB review is
a dynamic process that continues to change over time as
new controversies present themselves, and issues that
were at one time problematic become routine both within
individual IRBs and in the field of human subjects protec-
tion.
Table 1: The VA Quality Enhancement Research Initiative (QUERI)
The U.S. Department of Veterans Affairs' (VA) Quality Enhancement Research Initiative (QUERI) was launched in 1998. QUERI was designed to 
harness VA's health services research expertise and resources in an ongoing system-wide effort to improve the performance of the VA healthcare 
system and, thus, quality of care for veterans.
QUERI researchers collaborate with VA policy and practice leaders, clinicians, and operations staff to implement appropriate evidence-based 
practices into routine clinical care. They work within distinct disease- or condition-specific QUERI Centers and utilize a standard six-step process:
1) Identify high-risk/high-volume diseases or problems
2) Identify best practices
3) Define existing practice patterns and outcomes across the VA and current variation from best practices
4) Identify and implement interventions to promote best practices
5) Document that best practices improve outcomes
6) Document that outcomes are associated with improved health-related quality of life.
Within Step 4, QUERI implementation efforts generally follow a sequence of four phases to enable the refinement and spread of effective and 
sustainable implementation programs across multiple VA medical centers and clinics. The phases include:
1) Single site pilot,
2) Small scale, multi-site implementation trial,
3) Large scale, multi-region implementation trial, and
4) System-wide roll-out.
Researchers employ additional QUERI frameworks and tools, as highlighted in this Series, to enhance achievement of each project's quality 
improvement and implementation science goals.Implementation Science 2008, 3:10 http://www.implementationscience.com/content/3/1/10
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Results: The implementation research IRB 
experience
1. Implementation-specific issues
In this section, we present IRB challenges specific to
implementation research. Implementation research uses a
variety of methodologies at different stages and often
requires collaboration among disciplines [24]. Some
implementation research issues may not fit within the tra-
ditional human subjects paradigm used to assess clinical
trials. Risks in implementation research are generally
related to loss of confidentiality, rather than risks associ-
ated with drug treatments, as in traditional clinical trials.
The implementation-specific challenges introduced
below are: external validity considerations, Plan-Do-
Study-Act cycles, risk-benefit issues, the multiple roles of
researchers and subjects, and system-level unit of analysis.
a. External validity considerations
Most IRBs tend to be much more familiar with the ration-
ales for biomedical research procedures than with those
for implementation research. Two conceptual models can
be helpful in providing clear explanations for specific
aspects of implementation research that promote external
validity, and also bear on human subjects protection
issues – the Stetler Model of Research Utilization [25,26]
and the RE-AIM framework [27-29]. These models can be
incorporated in IRB applications by researchers, as appro-
priate, to inform their interactions with IRBs, as they
describe external validity considerations. While these
frameworks came to our attention after we had put much
thought into our approach to IRB issues, they may be
helpful to other researchers. These two models are pre-
sented briefly in Additional file 1: Implementation Evalu-
ation Theory: Stetler Model of Research Utilization and
RE-AIM.
b. Plan – Do – Study – Act (PDSA) intervention adaptation cycles
PDSA cycles are often a cornerstone of implementation
research. The nature of PDSA cycles means that imple-
mentation researchers may not be able to specify all
aspects of the project ahead of time for the IRB to judge
risk-benefit issues in the initial application. To change a
care system in a sustainable fashion, an "intervention"
must be both individualized to the resources and goals of
each site, and dynamic enough to take into account the
inevitability of changing conditions. PDSA cycles within a
particular study may incorporate multiple levels of form-
ative evaluation [4]. When formative evaluation results
Table 2: Description of our inter-related QUERI supported projects
Project Type Participants Goals
TIDES Action research 
partnership with 
formative evaluation
 Primary care, mental 
health, nursing and 
administrative leaders from 
three regional veterans 
health networks;
 Experienced depression 
care researchers; and
 Depressed veterans.
Study feasibility and safety of evidenced-based quality improvement for depression 
care. Steps included: 1) Adapt depression collaborative care models to VA 
settings through Evidence-Based Quality Improvement for Depression (EBQID); 
2) Support and evaluate depression collaborative care implementation; and 3) 
Prepare for dissemination of depression improvement methods and materials 
throughout the VHA.
WAVES Site-randomized 
controlled trial
 TIDES sites and matched 
control sites, and
 Veterans enrolled in 
primary care clinics 
screened for depression.
Implement & test depression collaborative care using TIDES evidence-based 
model.
COVES Mixed method; 
administrative data 
analysis and 
qualitative 
interviews
 Stakeholders (patients, 
clinicians, administrators), 
and
 Administrators of 
databases of veterans' 
records.
Understand cost and value tradeoffs of TIDES implementation using VA cost 
information and semi-structured interviews with TIDES stakeholders.
ReTIDES Regional 
demonstration 
project with 
program evaluation
All levels of VHA 
administrative structure 
including:
 Central Office,
 4 regional health 
networks and administrative 
control networks,
 VA medical centers,
 Clinics,
 Providers,
 Administrators, and
 Patients.
Support progress of TIDES collaborative care model toward national VHA 
implementation.
Sustain and spread TIDES evidence-based depression care model to additional 
VHA sitesImplementation Science 2008, 3:10 http://www.implementationscience.com/content/3/1/10
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are applied to the project, the equivalent of Plan Do Study
Act cycles [30] result in changes that may be unforeseen at
the beginning of the project.
We utilized two different approaches to address IRB con-
cerns resulting from PDSA cycles, depending upon the
preferences of each IRB. At the majority of our sites, we
submitted an initial protocol that was as complete as pos-
sible, given our site knowledge and expectations, and then
submitted modifications as needed. In situations where
the protocol was considered exempt, we consulted with
our IRB representative to ensure that the proposed modi-
fication would not alter the IRB's original decision that
the protocol was exempt. However after extensive discus-
sion and collaboration, other IRBs requested dividing the
Table 3: Implementation research themes, challenges and process aids
Theme Challenge Approach Process Aid(s)
Implementation-specific External validity considerations é Clearly explain & support issues.
é Use layperson language.
é Implementation Evaluation Theory: 
Stetler Model of Research Utilization 
& RE-AIM
PDSA intervention adaptation 
cycles
é Discuss with IRB and select 
component approach or 
modification approach.
Risk-benefit issues
(minimal risk)
é Request exemption or expedited 
review.
é Consider opinion letters.
é Clearly explain & support issues.
é Use lay person language.
Multiple roles of researchers/
facilitators & subject/participants
é Clearly explain roles and risk 
appropriate to each.
System-level unit of analysis é Clearly delineate various levels, 
risk appropriate, and justification for 
each.
Multiple health care systems/sites Transparency of system/researcher 
ethical responsibilities
é Specify division of responsibilities 
between researchers and site 
clinical staff.
é Project Implementation Charter & 
Site Memorandum of Agreement
Relationships among IRB and 
participating organizations
é Research through websites or 
personal contacts.
é Inquire about nature of oversight 
relationships.
é IRB Contact Questionnaire
Maintaining accountability across 
systems/sites
é Centralize records retention at a 
single administrative site.
é IRB Relational Database
Multiple local site PIs Recruitment é Communicate responsibilities, 
requirements, and level of 
commitment.
é Project Implementation Charter & 
Site Memorandum of Agreement
Varying levels of experience & 
limited time
é Orient to role responsibilities.
é Provide high level of administrative 
support.
é Site PI Orientation Checklist
Varying ethics certification 
requirements
é Investigate required trainings.
é Document approved trainings.
é IRB Relational Database
Varying levels of involvement é Invite participation in project 
related activities.
Multiple IRBs Lack of standardized procedures 
and forms
é Create template text to distribute 
to research team.
Communication with IRB/R&D 
Administrators
é Consider administrators integral 
members of research team.
é Communicate multi-site nature of 
project.
é IRB Contact Questionnaire
Multiple, competing renewal 
deadlines
é Budget time for form changes.
é Create deadline reports from 
database.
é IRB Relational Database
Variable AE definitions and 
reporting requirements
é Collect definitions, reporting 
requirements, etc.
é IRB Contact Questionnaire
Coordination & consistency in IRB 
related tasks
é Consider budgeting for an IRB 
Specialist position.
é Budget for sufficient resources.
é Use regular conference calls.
é IRB Specialist Position Description
é IRB Call Minute TemplateImplementation Science 2008, 3:10 http://www.implementationscience.com/content/3/1/10
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initial protocol into key component submissions, each
individually well specified.
Under this approach, we submitted the first study compo-
nent along with an overview of the entire project. We then
submitted additional project activities for individual
review in the context of the project overview. This
approach allowed IRB reviewers to judge project activities
in context without having to judge all components at
once. Reviewers had complete information for each com-
ponent at the time of submission. It allowed the level of
IRB review (i.e., exempt versus full) to be appropriate to a
specific component. At one study site, four consecutive
components were submitted individually and received
different IRB approvals.
Component 1 involved carrying out an expert panel to
decide how to best administer a depression collaborative
care project and was exempted. Component 2, staff qual-
itative interviews, was also exempted. Component 3, a
survey of site clinician opinions, was not exempted but
received a standard review and Waiver of Documentation
of Consent. The final component, a clinical decision sup-
port software tool developed by study participants (not
researchers), was acknowledged by the IRB as having been
received, but not reviewable, i.e., not research.
Over time, this component solution proved to be admin-
istratively burdensome to both the IRB and the research
team due to the need to track each component as a sepa-
rate application, complicating modifications and renew-
als. We anticipate that future IRB developments will
identify the best methods for introducing the unique fea-
tures of individual components to the IRB and, thereby,
will decrease the burden on both researchers and the IRB
[9].
c. Risk-benefit issues
Implementation research often involves both evidence-
based interventions carried out by clinical partners and
evaluation activities carried out by researchers. In QUERI
implementation research, the best practices to be imple-
mented are not experimental as earlier QUERI research
phases have already documented the need for clinical
improvement and provided an evidence base (Table 1).
Unless carefully explained and supported, we have found
that it may not be obvious to IRBs that the "research" issue
is not the efficacy of the best practice, but the ability of a
quality improvement strategy to introduce or improve a
system's ability to apply the evidence-based practice. IRBs
may not realize the extent to which quality improvement
principles and requirements guide clinical activities car-
ried out in implementation projects and, therefore, risk-
benefit issues might be most appropriately considered in
a QI framework. Currently, the determination as to
whether an activity is reviewable research or non-reviewa-
ble QI is made by the IRB. Unfortunately there is not yet a
standard method for assisting an IRB to make this deci-
sion.
In preparing our applications, to assist the IRB, we sought
to use clear layperson terminology to explain our project.
For example:
There are two aspects to this project that could be described
as "intervention:" 1) the system-level evidence-based qual-
ity improvement process that has the goal of changing
healthcare provider behavior, and 2) the depression care
that the providers deliver. This project studies the former.
The latter, described as collaborative care for depression,
has been extensively studied and is accepted as best practice
care. No experimental treatments are employed in this
project.
We have had some success in using an opinion letter proc-
ess as an initial step in the application process. For exam-
ple, one IRB (Table 4, Site I) considered a protocol to fall
under quality improvement and be classified as "non-
human" research, thus not requiring IRB review. How-
ever, for the same protocol another site required a full
submission. Given the societal health benefits likely to be
associated with researcher involvement with clinical sys-
tems and practices, and the known risks of poor quality
care, the ethical issues of adding burden to the process of
improving care should be considered in these determina-
tions [31,32].
Risks in implementation research are often elusive, and
the regulatory definition of "minimal risk" is imprecise.
There often are no physiological risks in implementation
research and, in the case of our studies, minimal psycho-
social risk, including psychological stress from complet-
ing staff interviews or surveys and evaluation discomfort.
Thus, implementation research might often be catego-
rized as minimal risk. However, breach of confidentiality
due to a security breach or human error remains a risk
even in minimal risk studies. Researchers should accu-
rately assess the associated risks of the research, including
the evidence-based practice.
Some systems provide expedited review for research
judged to be minimal risk. For example, our protocols
include evaluation through surveys, medical record
reviews, and stakeholder interviews. However, these mul-
tiple activities may result in complex IRB decision-making
and risk to the implementation activity timeline, if after
initial review the IRB decides that the study is inappropri-
ate for expedited review, and the study must be transferred
to the full-review mechanism. For example, one site
(Table 4, IRB C) stated, "If the survey was the only thingImplementation Science 2008, 3:10 http://www.implementationscience.com/content/3/1/10
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that came to the IRB board, it could have been exempt or
if the chart data had come to the IRB separately, it too,
could have been expedited. But because it came all
together, it would be hard to expedite it as a whole with
all the different components presented."
Finally, if an IRB judged the initial proposal to be exempt,
it became difficult to review a later modification of the
proposal. For example, this occurred when a staff survey
planned as an anonymous QI activity could not be feasi-
bly carried out without participant identifiability. It then
required extra effort to return to IRBs that had judged the
survey as exempt, in order to notify them of the new cir-
cumstances.
d. Multiple roles of researchers/facilitators & multiple subject/
participant classes
Sometimes it is not the implementation research practice
itself that is the risk, but ill-defined relationships among
researchers and the system with which they are working
Table 4: TIDES/RETIDES IRB initial application information
TIDES Study
Site* IRB type IRB required changes? Approval Type† Time Elapsed‡
A VA in-house No Exempt 32
B VA in-house No Exempt 67
C University Yes1 Expedited 75
D University No Expedited 9
E VA in-house Yes2 Expedited 5
F University Yes3 Full 7
G§ VA in-house No Full 82
H¶ University Yes4 Expedited 38
I University No Expedited 5
Average = 35.55
ReTIDES Study
F University Yes5 Full 22
I University N/A Non-human research 5
J University No Exempt 3
K University No Exempt 20
H¶ University Yes6 Expedited 30
L VA in-house Yes7 Expedited 14
A VA in-house No Exempt 6
M VA in-house No Exempt 14
Average = 14.25
* Site identification codes are uniform, showing both new sites for ReTIDES and some TIDES sites not (yet) participating in ReTIDES.
† We experienced no variance between review type preferred and actual approval type granted.
‡ In days, starting with submission date, ending with approval date (weekends, holidays included).
§ From IRB G Investigator Guide & Instructions booklet: "No research is exempt from review and there are no "expedited" reviews."
¶ This was the only site that required an electronic submission.
1 Concerns included: consent form alterations, include contact information in mailing, survey data storage, patient information protocol, number of 
interviews, and adding written consent at local level.
2 Concerns included: changes to allow better informed consent decision-making, protocol on frequency of subject contact, advance phone call 
consent, telephone interview protocol, recording interview protocol, time estimated for interviews, why patients were being interviewed, and 
obtaining consent.
3 Concerns included: consent obtained to access patient data registry, justification for exemption of worksheet data forms, how does VA encrypt 
medical records, number discrepancy, terminology issues, protocol regarding the movement of paper data, oral consent procedure, clarification of 
anonymous/confidential, changes to worksheets, who has data access, confirm study codes are not SSN, how is questionnaire used, and typographic 
errors.
4 Concerns included: typographic errors and further justification for no consent.
5 Concerns included: coercion as possible risk, determining coordinating center, providing a consent form if requested by subject, and how 
participation is/is not related to job description, including text about participating not affecting job security.
6 Concerns were administrative and related to the electronic submission process.
7 Concerns were administrative.Implementation Science 2008, 3:10 http://www.implementationscience.com/content/3/1/10
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that may add risk. Implementation researchers may best
be understood as facilitators or consultants within their
research projects, with no direct decision-making author-
ity in the intervention. Within our projects, researchers
were available as consultants to local site champions who
provided leadership for customizing and adapting the
intervention to the sites. Researchers also functioned as
consultants at the national level to encourage national
rollout of improved depression care. These different roles
(and risks) need to be clearly communicated with admin-
istrators and IRBs. For example, because our projects
involved depression treatment, it was important to estab-
lish suicidality risk-response protocols specifying activi-
ties of researchers and clinicians of which all parties were
aware.
Subjects, more appropriately called "participants," in
implementation research have different relationships
with researchers depending on their relationship to the
health care system in which the implementation takes
place. Participants may include providers, regional and/or
medical center leadership, and/or patients. Patients, for
example, may not encounter researchers, but have specific
aspects of their medical records examined for evidence
that is relevant to the implementation. Providers are cru-
cial in the success of clinical improvement efforts, how-
ever their role as a "subject" must be carefully considered.
If they see themselves as subjects from whom consent is
required for their participation, their buy-in and interest
in sustaining the improvement after the investigative
phase is over is likely to be vitiated. All classes of partici-
pants, or their representatives, may be involved as deci-
sion-makers in the specifics of the implementation. For
example, our project start-up meetings often included
nurse depression care managers, primary care physicians,
mental health practitioners, leadership/management per-
sonnel, and patient representatives. Clearly defining these
different roles and the risk appropriate to each will enable
the IRB to make an informed decision.
e. System-level unit of analysis
In these projects, like similar implementation efforts,
patients, providers and/or sites can be units of analysis to
measure/support the external validity of the implementa-
tion effort, as well as to monitor its clinical and organiza-
tional outcomes. The impact of implementation research
is often assessed on the patient level through patient
administrative records; at the provider level through sur-
vey results and aggregated, de-identified data; and at the
site level though cost analyses, site-level performance
measurements, interview results, and project records (i.e.,
conference call minutes, emails, etc.) analyses. IRBs that
are familiar with evaluating clinical trials may not under-
stand the necessity of collecting information at each of
these levels. Each of these levels has its own set of con-
cerns and ethical issues. For example, whereas breach of
confidentiality may be a major risk for patients, concern
that results of a survey may be accessible to supervisors
and used for evaluative purposes may be an issue for staff.
It is important to clearly delineate these various roles, the
risk appropriate to each, and the justification for each
when communicating with the IRB. Using clear layperson
language and/or tables to present relationships may be
useful.
2. Multiple health care systems/sites
This section focuses on concerns surrounding working
with multiple sites or health care systems, namely the eth-
ical responsibilities of researchers, preserving accountabil-
ity across sites, and relationships among IRBs and other
organizational entities.
a. Transparency of system/researcher ethical responsibilities
As consultants, researchers often function at the behest of
the organizational entity. Organizational participants
may hold considerably more power than the researchers
by virtue of their decision-making authority. Clinicians
may encounter implementation researchers as consult-
ants, purveyors of Continuing Medical Education and/or
as gatherers of information regarding professional opin-
ions and knowledge that may be relevant to the imple-
mentation project. IRBs are appropriately concerned
when researcher/clinician roles are complex, in that this
can raise issues of possible coercion in recruitment of
patients and staff, and/or confidentiality problems in
keeping clinical, job performance, and research data sepa-
rate.
We developed an Implementation Charter (see Addi-
tional file 2: Project Implementation Charter and Site
Memorandum of Agreement) with participating VA
regional networks that specified the division of responsi-
bilities between researchers and site clinical staff. For
example, the Charter indicated that we were responsible
for training depression care managers within the clinics,
but that the care managers were hired and supervised by
appropriate clinical personnel. It also specified our adher-
ence to clinical privacy rules for aspects of our project that
were quality improvement, and the need for site partici-
pants who wished to utilize any QI data from the project
for research purposes to seek IRB approval. This process
aid was successful in clarifying our roles and expectations
with participating sites.
b. Relationships among IRBs and participating organizations
Implementation researchers often need to satisfy multiple
sets of organizational reviews and requirements before
beginning a project. For example, within the VA system, a
research study conducted by VA personnel and/or involv-
ing VA patients cannot begin without both IRB approvalImplementation Science 2008, 3:10 http://www.implementationscience.com/content/3/1/10
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and approval by the appropriate local VA Research &
Development (R&D) Committee. While the IRB reviews
the protocol to ensure adequate protection of human sub-
jects, the local R&D committee provides the primary exec-
utive review for their site, assessing the overall scientific
merit of the protocol. R&D application procedures and
protocols are not uniform across sites.
We researched a new study site's local IRB and R&D
through web sites or personal contacts. To confirm that
we had the correct IRB forms for a particular submission,
we informally "interviewed" the IRB administrative con-
tact using our IRB Contact Questionnaire (see Additional
file 3: IRB Contact Questionnaire). Through this process
we obtained necessary information about the particular
IRB process, including their relationship with the local
R&D Committee. This process enabled us to effectively
submit our applications with minimal problems and
demonstrated our willingness to cooperate with local
administrators and procedures.
c. Maintaining accountability across systems/sites
As a site was brought onto a particular project, responsi-
bility for that site was assigned to specific research person-
nel within the project. This created continuity within the
submission process and in interactions between the IRB
and the project as a whole. Record retention has been cen-
tralized for the projects. Study personnel forward elec-
tronic and/or hard copies of all IRB paperwork and
communications to the administrative site in addition to
keeping copies at their respective sites. As the number of
sites increased across projects, it became clear that a rela-
tional database was necessary to efficiently track all the
paperwork and deadlines.
Using Microsoft ACCESS, information gathered from the
IRB Contact Questionnaire is entered into the database
(see Additional file 4: IRB Relational Database). As appli-
cations are submitted and approvals received, additional
key information is entered. The structure allows monitor-
ing expiration deadlines, duration between submission
and IRB approval, and time elapsed since submission.
Information for all sites or specific to project, site, or
region can be extracted and presented as reports. The data-
base is especially useful to track information at sites where
the component submission approach is utilized.
3. Multiple local site PIs
Enthusiastic, informed and active Site PIs are crucial to the
success of a multi-site study. The study staffs' ability to
finesse individual Site PI situations, accommodate the
desired level of Site PI involvement, and, generally, lim-
ited local support staff availability is crucial for the project
to be successful. As would be expected, we experienced
several challenges collaborating with multiple Site PIs,
such as recruitment, varying levels of experience and lim-
ited time, inconsistent ethics certification requirements,
and varying levels of commitment to the study.
a. Recruitment
We have used a variety of strategies when identifying and
recruiting local Site PIs. Through our contacts as research-
ers and established Site PI contacts, we were able to obtain
information on a potential Site PIs' availability and over-
all interest. The initial conversation between the project PI
and potential Site PI covered background information on
the project, noting other clinicians who may be participat-
ing in the project, and a brief overview of responsibilities.
An assigned member of the research staff followed up
with the Site PI to further address questions. Communi-
cating Site PI responsibilities, requirements, and level of
commitment clearly and accurately is necessary for suc-
cess. We used the Implementation Charter mentioned ear-
lier to help clarify the role of the Site PI in relation to the
researchers (See Additional file 2: Project Implementation
Charter and Site Memorandum of Agreement). It is critical
that the involvement of the site PI is supported by their
organizational supervisors and relevant to their own
career goals.
b. Varying levels of experience & limited time
After recruitment, the research team must assess the expe-
rience level of Site PIs with regard to their local IRB, the
IRB process and responsibilities, and our project(s). One
consistent factor among our Site PIs was their busy sched-
ules and limited availability. As a result, we developed an
efficient, concise protocol to gather this information
through our Site PI Orientation Checklist (see Additional
file 5: Site PI Orientation Checklist). Upon completion of
the Checklist, roles and responsibilities of the research
staff and Site PI were clearly delineated, including who
would handle the majority of IRB paperwork. At some
sites, research staff effectively became the research coordi-
nator for the local Site PI. A Site PI's willingness to assist
in problem-solving proved to be critical to the timeliness
with which each site progressed through the IRB process.
For example, some IRBs do not include remotely-based
research staff on correspondence relating to the project.
Site PIs are encouraged to proactively forward those docu-
ments to their research staff contact person to ensure opti-
mal project responsiveness to IRB requirements and to
minimize project delays.
d. Varying ethics certification requirements
All researchers are responsible for fulfilling any necessary
ethics certification and training requirements prior to the
start of any research. However, different sites may require
renewals of these trainings at different times and may
require additional certification. It is in the project's inter-
est to monitor these requirements to avoid any projectImplementation Science 2008, 3:10 http://www.implementationscience.com/content/3/1/10
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delay due to a lapse in training certification. The relational
database mentioned above can be used for this purpose
(see Additional file 4: IRB Relational Database).
d. Varying levels of involvement
Site PIs demonstrate varying levels of involvement to their
role within the project. Some take an active role in com-
municating new ideas and suggestions regarding imple-
mentation, or independently promoting and presenting
the project at conferences or meetings with clinicians. To
help provide incentive, we try to involve interested Site PIs
in project-related activities, such as workgroup meetings.
Several of these working groups have developed and pub-
lished manuscripts.
4. Multiple IRBs
For researchers who have the need, the logistics of work-
ing with multiple IRBs are discussed below. These include:
lack of standardized procedures and forms, communica-
tion with IRB administrators, multiple competing renewal
deadlines, variable adverse event reporting requirements
and definitions, and issues with coordination and consist-
ency of IRB-related tasks.
a. Lack of standardized procedures & forms
Our experience is that IRB procedures, forms, deadlines
and meeting schedules vary from one IRB to the next.
Areas of variability include: whether the IRB will commu-
nicate directly with staff other than the Site PI, structure
and organization of application forms, deadlines and
meeting schedules, and reporting requirements for
adverse events. This diversity increases the burden on
research staff. We developed a consistent approach to sub-
missions. One senior member of our research staff com-
posed the "template" text that was subsequently
distributed to other research staff members, who tailored
the text to best fit a particular IRB.
b. Communications with IRB and R&D administrators
The multi-site nature of our projects means that in the
majority of cases, the project PI, Site PI, and research staff
are in different geographical locations. Communicating
this to respective administrators enables them to under-
stand the constraints of the situation and, in some cases,
resulted in their exceptional assistance in the submission
process. For instance, one R&D Administrator offered to
collect the necessary Site PI signatures for submissions,
hand deliver the paperwork to the IRB, and inform the
research team via e-mail.
At the start of the projects in 2001, many IRBs did not
have websites, or if they did, all necessary forms and
instructions were not available on the site. This required
the assistance of the site's IRB staff in order to obtain all
forms and any additional relevant information on the
submission process. Today, even with many forms and
instructions available online, it is crucial to communicate
with IRB staff to ensure the correct forms are used to fit a
particular activity (see Additional file 3: IRB Contact
Checklist). Considering IRB and R&D staff as integral
members of a QI effort helps minimize communication
difficulties and facilitate the sometimes cumbersome IRB
process.
c. Multiple competing renewal deadlines
Carrying out projects involving multiple IRBs creates a
revolving door of renewal deadlines. This requires that the
research team monitor the approval status of each site.
Renewal forms change over time as IRBs revise old ques-
tions and add new ones. It is important to take this into
consideration when budgeting the amount of time
needed for IRB activities.
All of our IRB submissions are tracked through the rela-
tional database, and bi-weekly submission deadline
reports are created that are shared with other coordinating
administrative sites (see Additional file 4: IRB Relational
Database) using group emails and IRB-specific conference
calls.
d. Variable adverse event definitions & reporting requirements
Implementation projects involve the possibility of adverse
events that, although not directly connected with study
activities, may need to be reported to involved IRBs. Since
our projects work with a depressed population, we pre-
pared for the eventuality of a serious or successful suicide
attempt. We discussed this potential risk in IRB applica-
tions and collected different IRB definitions, reporting
requirements, and related items for Adverse Events (AEs)
and Serious Adverse Events (SAEs) (see Additional file 3:
IRB Contact Questionnaire).
There is a significant degree of variation in AE/SAE defini-
tions and reporting requirements illustrated by the fol-
lowing hypothetical situation of a completed suicide by a
study patient. One IRB would consider this a reportable
SAE, because a subject died. A second IRB would consider
it a reportable SAE because suicide is an expected risk
among this study population. A third IRB would not con-
sider it a reportable event because it was believed not to be
related to the study procedures, since all established med-
ical center and research policies and procedures were
appropriately followed.
e. Coordination & consistency in IRB-related tasks
All the process aids and approaches mentioned above can
not be fully realized without coordination, consistency,
advanced planning and consultation. For example, while
developing the IRB portion of our grant applications, we
consulted with several IRB experts. IRB work for imple-Implementation Science 2008, 3:10 http://www.implementationscience.com/content/3/1/10
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mentation projects is a significant resource allocation and
budget issue. It may be cost-effective to budget for an IRB
specialist to assist research staff. This specialist should
have extensive knowledge of Human Subjects protection
issues and the IRB system in which the study takes place
(see Additional file 6: IRB Specialist Position Descrip-
tion). In our case, other project staff devoted approxi-
mately 1.5 FTEE (Full time employment equivalent) to
IRB-related tasks over all study years (6 years, at present),
with significant involvement both by investigators and
research coordinators.
Regular conference calls were established to anticipate
and discuss IRB issues within the projects. These calls
ensure that research staff can discuss and resolve IRB con-
cerns (see Additional file 7: IRB Call Minutes). While this
effort is substantial, similar projects should anticipate rel-
evant IRB challenges and budget appropriately.
Discussion
The IRB system in the United States is overburdened,
affecting all types of research, particularly implementa-
tion research. Specific aspects of implementation research
interact with variations in knowledge, procedures and reg-
ulatory interpretations across IRBs to impact the imple-
mentation and study of best methods to increase
evidence-based practice. Through lack of unambiguous
guidelines and local liability concerns, IRBs are at risk of
applying both variable and inappropriate or unnecessary
standards that may impede the conduct of evidence-based
QI implementation research because they are not consist-
ent with the spirit of the Belmont Report, a summary of
the three basic ethical principles (Respect for persons,
Beneficence, and Justice) identified by the National Com-
mission for the Protection of Human Subjects of Biomed-
ical and Behavioral Research. However, there are
promising developments in the IRB community. For
instance, in November 2005, the Office for Human
Research Protections (OHRP) sponsored a workshop on
alternative models for IRB review, including Centralized
IRBs, with a follow-up conference in 2006 [33,34]. Efforts
to accredit IRBs may increase uniformity and the IRB's
ability to be a full partner in improving care. In the mean-
time, it is incumbent upon implementation researchers to
interact with IRBs in a manner that assists appropriate
risk/benefit determinations and helps prevent the process
from having a negative impact on efforts to reduce the lag
in implementing best practices.
Conclusion
IRBs are essential participants in moving implementation
research forward. Our experience shows that ethical
dilemmas posed by implementation research can be
solved if the level of commitment and communication
among stakeholders is sufficient. Our experience also
highlights the high costs of working with IRBs in multi-
site projects, and the necessity of developing organized,
efficient ways of dealing with these issues if researchers are
to participate in improving clinical quality.
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